(12) **Translation of european patent specification**

(11) **NO/EP 2707366 B1**

NORWAY

(19) NO
(51) Int Cl.
C07D 409/10 (2006.01)
A61K 31/70 (2006.01)
C07H 7/04 (2006.01)

Norwegian Industrial Property Office

(21)	Translation Published	2015.11.23
(80)	Date of The European Patent Office Publication of the Granted Patent	2015.06.24
(86)	European Application Nr.	12723013.4
(86)	European Filing Date	2012.05.09
(87)	The European Application's Publication Date	2014.03.19
(30)	Priority	2011.05.09, US, 201161483887 P
(84)	Designated Contracting States:	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
	Designated Extension States:	BA ME
(73)	Proprietor	Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse, BE-Belgia
(72)	Inventor	NGUYEN, Minh, 18 Bearse Avenue, Apt. 3, DorchesterMA 02124, US-USA COLLIER, Edwin, A., C/o Janssen Research&Development Llc1000 Route 202, RaritanNJ 08869, US-USA
(74)	Agent or Attorney	Oslo Patentkontor AS, Postboks 7007 Majorstua , 0306 OSLO, Norge

(54) Title **L-PROLINE AND CITRIC ACID CO-CRYSTALS OF (2S, 3R, 4R, 5S, 6R)- 2- (3- ((5- (4-FLUOROPHENYL)THIOPHEN-2-YL) METHYL) -4-METHYLPHENYL)-6-(HYDROXYMETHYL)TETRAHYDRO-2H-PYRAN-3,4,5-TRIOL**

(56) References Cited:

WO-A1-2009/026537
US-A1- 2005 233 988
US-A1- 2008 146 515
NOMURA S ET AL: "Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus (1)", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 53, no. 17, 9 September 2010 (2010-09-09), pages 6355-6360, XP007915324, ISSN: 0022-2623, DOI: 10.1021/JM100332N
VISHWESHWAR P ET AL: "Pharmaceutical co-crystals", JOURNAL OF PHARMACEUTICAL SCIENCES, AMERICAN PHARMACEUTICAL ASSOCIATION, WASHINGTON, US, vol. 95, no. 3, 1 March 2006 (2006-03-01), pages 499-516, XP002443334, ISSN: 0022-3549, DOI: 10.1002/JPS.20578
NATE SCHULTHEISS ET AL: "Pharmaceutical Cocrystals and Their Physicochemical Properties", CRYSTAL GROWTH & DESIGN, vol. 9, no. 6, 3 June 2009 (2009-06-03), pages 2950-2967, XP55011939, ISSN: 1528-7483, DOI: 10.1021/cg900129f
SHAN N ET AL: "The role of cocrystals in pharmaceutical science", DRUG DISCOVERY TODAY, ELSEVIER, RAHWAY, NJ, US, vol. 13, no. 9-10, 1 May 2008 (2008-05-01) , pages

440-446, XP022649919, ISSN: 1359-6446, DOI: 10.1016/J.DRUDIS.2008.03.004 [retrieved on 2008-04-22]

Patentkrav:

1. L-prolin-kokrystall av en forbindelse med formel (I-X)



(I-X).

2. L-prolin-kokrystall ifølge krav 1, hvor kokrystallen er krystallinsk.

3. L-prolin-kokrystall ifølge krav 2, omfattende de følgende pXRD-topper °2θ: 3,74, 9,50, 10,98, 17,78, 18,62, 21,94, 23,43 og 26,82.

4. L-prolin-kokrystall ifølge krav 2, hvor kokrystallen oppviser et smeltepunkt på 188°C, målt ved DSC.

5. Sitronsyre-kokrystall av en forbindelse med formel (I-X)



(I-X).

6. Sitronsyre-kokrystall ifølge krav 5, hvor kokrystallen er krystallinsk.

7. Sitronsyre-kokrystall ifølge krav 6, omfattende de følgende pXRD-topper °2θ: 4,2, 9,16, 12,39, 16,54, 17,69, 19,70, 23,63 og 25,66.

8. Sitronsyre-kokrystall ifølge krav 6, hvor kokrystallen oppviser et smeltepunkt på rundt 156°C, målt ved DSC.